{"doi":"10.1093/infdis/jiae260","title":"Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results","abstract":"BACKGROUND: Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics. METHODS: We conducted a prospective cohort study of PWH aged ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24 and 48 weeks later. The primary end point was viral suppression (<200 copies/mL) at 48 weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500 copies/mL. RESULTS: We enrolled 500 participants (median age 47 years; 41% women). At 48 weeks after TLD transition, 94% of participants were in care with a VL <200 copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500 copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events. CONCLUSIONS: High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region. CLINICAL TRIALS REGISTRATION: NCT04066036.","journal":"The Journal of Infectious Diseases","year":2024,"id":427335,"datarank":0.6018795656018052,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.18599125726583793,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.18599125726583793,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":10,"citers_with_citation_signal":5,"citers_with_endowment":5,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8755,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04066036"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":416058,"name":"Winnie Muyindike","orcid":"0000-0002-6694-2645","position":1,"is_corresponding":false},{"id":1228006,"name":"Victoria Nanfuka","orcid":null,"position":2,"is_corresponding":false},{"id":1094532,"name":"Daniel Omoding","orcid":"0000-0002-8800-5732","position":3,"is_corresponding":false},{"id":1228007,"name":"Nimusiima Komukama","orcid":null,"position":4,"is_corresponding":false},{"id":1228008,"name":"Ian T. Barigye","orcid":null,"position":5,"is_corresponding":false},{"id":1228009,"name":"Lydia Kansiime","orcid":null,"position":6,"is_corresponding":false},{"id":1228010,"name":"Justus Tumusiime","orcid":null,"position":7,"is_corresponding":false},{"id":1034473,"name":"Taing N. Aung","orcid":"0000-0001-6934-9938","position":8,"is_corresponding":false},{"id":888774,"name":"Ashley Stuckwisch","orcid":null,"position":9,"is_corresponding":false},{"id":326169,"name":"Bethany Hedt‐Gauthier","orcid":"0000-0002-9689-5413","position":10,"is_corresponding":false},{"id":104965,"name":"Vincent C. Marconi","orcid":"0000-0001-8409-4689","position":11,"is_corresponding":false},{"id":282139,"name":"Mahomed‐Yunus S. Moosa","orcid":"0000-0001-6191-4023","position":12,"is_corresponding":false},{"id":69670,"name":"Deenan Pillay","orcid":"0000-0003-2431-244X","position":13,"is_corresponding":false},{"id":282131,"name":"Jennifer Giandhari","orcid":"0000-0002-2944-4583","position":14,"is_corresponding":false},{"id":69666,"name":"Richard Lessells","orcid":"0000-0003-0926-710X","position":15,"is_corresponding":false},{"id":69659,"name":"Ravindra K. Gupta","orcid":"0000-0001-9751-1808","position":16,"is_corresponding":false},{"id":69650,"name":"Mark J. Siedner","orcid":"0000-0003-3506-842X","position":17,"is_corresponding":false},{"id":584834,"name":"Suzanne M. McCluskey","orcid":"0000-0001-8463-5430","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T01:58:47.805440Z","pmid":"38748986","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}